• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泮托拉唑是一种新型质子泵抑制剂,具有精确且可预测的活性特征。

Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity.

作者信息

Parsons M E

机构信息

Biosciences Division, University of Hertfordshire, Hatfield, UK.

出版信息

Eur J Gastroenterol Hepatol. 1996 Oct;8 Suppl 1:S15-20. doi: 10.1097/00042737-199610001-00004.

DOI:10.1097/00042737-199610001-00004
PMID:8930575
Abstract

UNLABELLED

MECHANISM OF ACTION OF PANTOPRAZOLE: Pantoprazole, a new proton-pump inhibitor, is a drug which demonstrates precision from the molecular level to the patient. Like other H+, K(+)-ATPase inhibitors it has in-built selectivity because it accumulates in the acidic compartment of the parietal cell and has to be acid-activated before it acts on the proton pump.

STABILITY OF PANTOPRAZOLE

Pantoprazole is chemically more stable than the other proton-pump inhibitors, particularly at near neutral pH, and therefore is unlikely to interact with thiol-containing proteins outside the parietal cell. This acid stability may also account for its highly selective binding to the two cysteine groups located in the proton-pumping pathway of the enzyme.

CONCLUSIONS

Pantoprazole is characterized by a degree of pharmacokinetic precision not associated with the other drugs. It shows linear kinetics after oral and intravenous administration. It has a high and constant bioavailability (approximately 77%) which does not change on multiple dosing, so that maximum blood levels are achieved after the first dose. Bioavailability is not altered by concomitant antacid administration, and dose adjustment is not required in elderly patients or those with chronic renal impairment. Extensive studies in man have found no interaction with other drugs. Because of this pharmacokinetic profile, a standard doses of 40 mg is optimal and can be used with confidence in subgroups of patients to give a predictable therapeutic effect.

摘要

未标注

泮托拉唑的作用机制:泮托拉唑是一种新型质子泵抑制剂,是一种从分子水平到患者均表现出精准性的药物。与其他H⁺,K⁺-ATP酶抑制剂一样,它具有内在选择性,因为它在壁细胞的酸性区室中蓄积,并且在作用于质子泵之前必须被酸激活。

泮托拉唑的稳定性

泮托拉唑在化学性质上比其他质子泵抑制剂更稳定,尤其是在接近中性pH值时,因此不太可能与壁细胞外含硫醇的蛋白质相互作用。这种酸稳定性也可能解释了它与位于该酶质子泵途径中的两个半胱氨酸基团的高度选择性结合。

结论

泮托拉唑具有一定程度的药代动力学精准性,这是其他药物所没有的。口服和静脉给药后呈线性动力学。它具有高且恒定的生物利用度(约77%),多次给药时不会改变,因此首次给药后即可达到最高血药浓度。同时服用抗酸剂不会改变生物利用度,老年患者或慢性肾功能损害患者无需调整剂量。在人体进行的广泛研究未发现与其他药物有相互作用。由于这种药代动力学特征,40毫克的标准剂量是最佳的,可放心用于患者亚组以产生可预测的治疗效果。

相似文献

1
Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity.泮托拉唑是一种新型质子泵抑制剂,具有精确且可预测的活性特征。
Eur J Gastroenterol Hepatol. 1996 Oct;8 Suppl 1:S15-20. doi: 10.1097/00042737-199610001-00004.
2
Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.质子泵抑制剂兰索拉唑、奥美拉唑和泮托拉唑与其他药物的代谢相互作用。
Eur J Gastroenterol Hepatol. 1996 Oct;8 Suppl 1:S21-5. doi: 10.1097/00042737-199610001-00005.
3
Clinical experience with pantoprazole in gastroesophageal reflux disease.泮托拉唑治疗胃食管反流病的临床经验
Clin Ther. 2000 Oct;22(10):1169-85; discussion 1149-50. doi: 10.1016/s0149-2918(00)83061-1.
4
Pantoprazole.泮托拉唑
Am J Health Syst Pharm. 2001 Jun 1;58(11):999-1008. doi: 10.1093/ajhp/58.11.999.
5
Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.综述文章:质子泵抑制剂的持续发展,尤其涉及泮托拉唑
Aliment Pharmacol Ther. 1995 Aug;9(4):363-78. doi: 10.1111/j.1365-2036.1995.tb00394.x.
6
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.泮托拉唑:其药理特性及在酸相关性疾病管理中的治疗应用的最新进展。
Drugs. 2003;63(1):101-33. doi: 10.2165/00003495-200363010-00006.
7
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.酸泵抑制剂的药代动力学、代谢及相互作用。重点关注奥美拉唑、兰索拉唑和泮托拉唑。
Clin Pharmacokinet. 1996 Jul;31(1):9-28. doi: 10.2165/00003088-199631010-00002.
8
Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.奥美拉唑、兰索拉唑、泮托拉唑和雷贝拉唑治疗酸相关性疾病的疗效评估。
J Am Pharm Assoc (Wash). 2000 Jan-Feb;40(1):52-62; quiz 121-3. doi: 10.1016/s1086-5802(16)31036-1.
9
Pantoprazole: a new proton pump inhibitor.泮托拉唑:一种新型质子泵抑制剂。
Clin Ther. 2000 Nov;22(11):1268-93. doi: 10.1016/s0149-2918(00)83025-8.
10
Pantoprazole, Prout and the proton pump.泮托拉唑、普劳特与质子泵
Hosp Med. 1999 Jul;60(7):500-4. doi: 10.12968/hosp.1999.60.7.1743.

引用本文的文献

1
Characteristics of the Human Upper Gastrointestinal Contents in the Fasted State Under Hypo- and A-chlorhydric Gastric Conditions Under Conditions of Typical Drug - Drug Interaction Studies.在典型药物相互作用研究条件下,胃酸过少和无胃酸状态下禁食的人体上消化道内容物的特征。
Pharm Res. 2016 Jun;33(6):1399-412. doi: 10.1007/s11095-016-1882-8. Epub 2016 Mar 14.
2
Pantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleeding.泮托拉唑用于治疗消化性溃疡出血及预防再出血。
Clin Med Insights Gastroenterol. 2012 Sep 17;5:51-60. doi: 10.4137/CGast.S9893. eCollection 2012.
3
Potent gastric acid inhibition in Helicobacter pylori eradication.
幽门螺杆菌根除治疗中强效胃酸抑制作用
Drugs. 2005;65 Suppl 1:83-96. doi: 10.2165/00003495-200565001-00012.
4
Pharmacokinetics of proton pump inhibitors in children.质子泵抑制剂在儿童中的药代动力学
Clin Pharmacokinet. 2005;44(5):441-66. doi: 10.2165/00003088-200544050-00001.
5
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.泮托拉唑:其药理特性及在酸相关性疾病管理中的治疗应用的最新进展。
Drugs. 2003;63(1):101-33. doi: 10.2165/00003495-200363010-00006.
6
Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition.医院环境中抑酸的药理学:聚焦于质子泵抑制
Crit Care Med. 2002 Jun;30(6 Suppl):S356-61. doi: 10.1097/00003246-200206001-00003.